Skip to content
Open access

Aberrant excitatory neuronal ERBB4 promotes Alzheimer’s disease pathology

Aug 2026 · Nature · Vol 658, pp. 725 - 735 · 2 citations · ⚡ 1 influential · 60 references
Medicine

TL;DR

It is demonstrated that, during AD progression in mice, astrocytes and microglia increase phagocytic elimination of excitatory synapses while reducing elimination of inhibitory synapses, suggesting that neuroinflammation alone may be dispensable for early AD synapse loss.

Abstract

Neuroinflammation and synapse loss are associated with cognitive decline in Alzheimer’s disease (AD). Although microglial hyperphagocytic activity has been implicated in synapse loss1, 2, 3–4, the mechanisms underlying these pathologies remain obscure. Here we demonstrate that, during AD progression in mice, astrocytes and microglia increase phagocytic elimination of excitatory synapses while reducing elimination of inhibitory synapses, suggesting that neuroinflammation alone may be dispensable for early AD synapse loss. Instead, single-nucleus RNA-sequencing analysis identified the emergence of early-responsive excitatory neurons (EREN), characterized by expression of ectopic Erb-B2 receptor tyrosine kinase 4 (Erbb4), as one of the earliest major alterations in AD mouse models. Selective Erbb4 deletion in AD excitatory neurons abrogated abnormal neuronal network activities and synapse loss, as well as reactive gliosis, amyloid plaque deposition and cognitive deficits. Conversely, Erbb4 overexpression in wild-type excitatory neurons recapitulated these core AD-like phenotypes without amyloid plaques. Mechanistically, these effects required mammalian target of rapamycin (mTOR) signalling downstream of ERBB4. Subsequent transcriptomic analyses showed that excitatory neuronal Erbb4 is both necessary and sufficient to induce EREN and reactive gliosis. Directed mediation analysis of human AD transcriptomic data further support a model in which excitatory neuronal ERBB4 contributes to a pathogenic cascade that links amyloid pathology to tau propagation and cognitive decline. These findings identify aberrant Erbb4 expression in excitatory neurons as an early driver of AD pathophysiology and a potential therapeutic target across neurodegenerative diseases. Neuroinflammation alone may be dispensable for early synapse loss in Alzheimer’s disease.

Read PDF

Similar papers

Review Open access Aug 2026

Microglia-mediated neuroinflammation in Alzheimer’s disease: mechanisms and emerging therapeutic targets

A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...

Lian-Jing Xu, Ying Zhang, Li Jiang et al. · 0 citations
Open access Aug 2026

Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity

The findings establish the retina as an early site of AD synaptopathy and position UCHL1 as a candidate biomarker and mechanistic mediator linking amyloid pathology, neuroinflammation, and synaptic vulnerability.

A. Rentsendorj, Jean-Philippe Vit, Alexandre Hutton et al. · 0 citations
Review Open access Sep 2026

Is there a role for B cells in Alzheimer's disease?

The phenotypic and functional alterations of B cells in AD are reviewed, integrating evidence from experimental models and human studies to evaluate whether B cells constitute an underappreciated component of the adaptive immune response in AD and whether they represent a compelling immunotherapeutic target.

Eva-Loren Charavner, S. Fillatreau, M. El Behi · 0 citations
Review Open access Oct 2026

Microglial Therapeutic Potential in Alzheimer’s Disease: From Phenotypic Diversity to Targeted Interventions

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) deposition, tau pathology and cognitive decline. Increasing evidence from genetic, transcriptomic, experimental and clinical studies has identified microglia as key regulators of AD pathogenesis. Under physiological con...

Maria-Raluca Gogu, Ivona Mazarianu, G. Stanciu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.